Advertisement

Control of TGEV mRNA Transcription

  • Julian Hiscox
  • David H. Pocock
  • Paul Britton
Chapter
  • 228 Downloads
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 342)

Abstract

Coronavirus proteins are translated from a nested set of subgenomic mRNAs which have common 3’ termini with unique 5’ extensions. Evidence suggests that coronavirus mRNAs are generated by a mechanism of leader primed transcription. Leader RNA binds to consensus sequences upstream of each gene on full length negative strand viral RNA and transcription proceeds to the 5’ end of the negative strand to produce the nested set of mRNAs. Even though this gives rise to polycistronic mRNA species only the 5’ extension of each mRNA is translated to give the viral proteins. The leader RNA for TGEV is about 90 nucleotides long and contains the sequence which recognises the leader binding sites on the negative strand RNA. Evidence suggests that the length of the leader binding sequence may be involved in transcriptional control of individual mRNAs. In order to investigate this a virus specific mRNA isolation method was developed to measure the relative amounts of mRNAs synthesised during an infection of LLC-PK1 cells with TGEV (strain FS772/70). Thus the relative quantity of each mRNA can be determined and correlated with the variation in size of the leader binding site.

Keywords

Magnetic Bead Negative Strand Guanidinium Isothiocyanate Streptavidin Magnetic Bead Incomplete Transcript 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    L.P. Doyle and L.M. Hutchings, J. Amer. Vet. Med. Assoc. 108:257–259 (1946).Google Scholar
  2. 2.
    D.J. Games, D.H. Pocock and B.V. Pike, J. Gen. Virol. 32:283–294 (1976).CrossRefGoogle Scholar
  3. 3..
    K. McIntosh, R.K. Chao, H.E. Krause, R. Wasil, H.E. Mocega and M.A. Mufson, J. Infect. Dis. 130:502–510 (1974).PubMedCrossRefGoogle Scholar
  4. 4.
    H. Wege, S. Siddell and V. ter Meulen, Curr. Top. Microbiol. Immunol. 99:165–200 (1982).PubMedCrossRefGoogle Scholar
  5. 5.
    B. Lomniczi, J. Gen. Virol. 36:531–533 (1977).PubMedCrossRefGoogle Scholar
  6. 6.
    R.S. Bark, S.A. Stohlman and M.M.C. Lai, J. Virol. 48:633–640 (1983).Google Scholar
  7. 7.
    K.W. Page, P. Britton and M.E.G. Boursnell, Virus Genes 4:289–301. (1990).PubMedCrossRefGoogle Scholar
  8. 8.
    P.B. Sethna, S.L. Hung and D.A. Brian, Proc. Natl. Acad. Sci. USA 86:5626–5630 (1989).PubMedCrossRefGoogle Scholar
  9. 9.
    P. Chomczynski and N. Sacchi, Anal. Biochem. 162:156–159 (1987).PubMedCrossRefGoogle Scholar
  10. 10.
    K.S. Jacobsen, E. Breivold and E. Hornes, N.A.R. 18:3669 (1990).CrossRefGoogle Scholar
  11. 11.
    M. Uhlen, Nature. 340:733–734 (1989).PubMedCrossRefGoogle Scholar
  12. 12.
    S. Ekenberg, M. McKormick, L. Wu and C. Smith, Promega Notes. 39:7–10 (1992).Google Scholar
  13. 13.
    A. Pahler, W.A. Hendrickson, M.A. Gawinowicz-Kolks, C.E. Argarana and C.R. Cantor, J. Biol. Chem. 262:13933–13937 (1987).PubMedGoogle Scholar
  14. 14.
    M.C. Clarke, J. Gen. Virol. 3:276–270 (1968).Google Scholar
  15. 15.
    D.A. Kennedy and C.M. Johnson-Lussenberg, J. Virol. 29:401–404 (1979).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Julian Hiscox
    • 1
  • David H. Pocock
    • 1
  • Paul Britton
    • 1
  1. 1.Division of Molecular BiologyA.F.R.C., Institute for Animal HealthCompton, Newbury, BerkshireUK

Personalised recommendations